Highlights in HIV 2022-2024

Area of Science:

• Infectious Diseases
• Public Health
• Clinical Medicine

Background:

• The period 2022-2024 has seen significant developments in HIV research and clinical practice.
• Understanding current HIV epidemiology and healthcare professional knowledge is crucial for effective prevention and management.
• The REPRIEVE study presents key findings impacting the care of individuals with HIV.

Purpose of the Study:

• To summarize recent global publications and conference presentations on HIV infection.
• To provide updated epidemiological data for HIV in Spain.
• To review advancements in antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP).

Main Methods:

• Literature review of publications and international conference presentations from 2022-2024.
• Analysis of epidemiological data specific to Spain.
• Assessment of healthcare professionals' knowledge on HIV transmission and prevention.
• Discussion of significant clinical studies, such as the REPRIEVE trial.

Main Results:

• Recent data indicates evolving trends in HIV epidemiology within Spain.
• Healthcare professionals' knowledge levels regarding HIV transmission and prevention require ongoing assessment and education.
• The REPRIEVE study highlights the importance of addressing comorbidities in people living with HIV.
• New antiretroviral therapy regimens, including dual therapy and long-acting injectables, show promise for improved patient management.

Conclusions:

• The field of HIV management is rapidly advancing with new therapeutic options.
• Continued education for healthcare professionals is essential to keep pace with HIV research.
• Updated epidemiological surveillance and targeted interventions remain critical for HIV control.
• Innovations in treatment, such as dual therapy and long-acting injectables, offer improved strategies for managing HIV infection.